Bio/Pharma News

Oct 11, 2017
By Pharmaceutical Technology Editors
Johnson & Johnson’s Janssen Sciences Ireland UC will invest more than EUR 300 million (US$355 million) to expand manufacturing capacity for biologic medicines at its Ireland facility.
Oct 11, 2017
By Pharmaceutical Technology Editors
The company is considering options for a full or partial separation of its Consumer Healthcare business, either through a spin-off, sale, or other transaction.
Oct 11, 2017
By Pharmaceutical Technology Editors
Xellia Pharmaceuticals invests US$25 million in its Copenhagen, Denmark site to expand sterile manufacturing of products for treating antimicrobial resistant infections.
Oct 11, 2017
By Pharmaceutical Technology Editors
BARDA has entered a $12-million contract with biopharmaceutical firm Achaogen for the late-stage development of an antibiotic against resistant bacteria, and as a potential treatment for biowarfare agents.
Oct 11, 2017
By Pharmaceutical Technology Editors
AstraZeneca is seeking approval for its anti-cancer monoclonal antibody, Imfinzi, for treating non-small cell lung cancer in the European Union.
Oct 11, 2017
By Pharmaceutical Technology Editors
Amgen is seeking approval for an additional indication in glucocorticoid-induced osteoporosis for its blockbuster osteoporosis therapeutic, Prolia.
Oct 04, 2017
By Pharmaceutical Technology Editors
The Danish biotechnology company has been awarded a sole-source BARDA contract valued at more than $539 million for a freeze-dried smallpox vaccine.
Oct 04, 2017
By Pharmaceutical Technology Editors
Under Project BioShield, the agency could provide more than $170 million in funding to purchase and support late-stage development of Ebola vaccines and therapeutic drugs.
Oct 03, 2017
By Pharmaceutical Technology Editors
The alliance gives Celgene an option to acquire programs run by Nimbus Therapeutics for developing therapeutics to treat autoimmune disorders.
Oct 02, 2017
By Pharmaceutical Technology Editors
A grant from the Bill & Melinda Gates Foundation will advance PnuVax’s pneumonia vaccine’s clinical development and biomanufacturing scale-up using a low-cost manufacturing approach.
native1_300x100
lorem ipsum